Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11269992 | 0.82 | SIGMAR1 (0.41) | TMEM97SIGMAR1 | |
| SCHEMBL11278589 | 0.82 | HRH3 (0.37) | TMEM97HRH3 | |
| Hydrochloric Acid SCHEMBL11281719 | 0.81 | SIGMAR1 (0.40) | TMEM97SIGMAR1 | |
| SCHEMBL11407006 | 0.76 | CASP3 (0.59) | KAT2AKAT2BCASP3 | |
| SCHEMBL11348382 | 0.75 | CASP3 (0.57) | KAT2AKAT2BCASP3 | |
| Hydrochloric Acid SCHEMBL11272284 | 0.73 | CASP3 (0.56) | KAT2AKAT2BCASP3 | |
| SCHEMBL15680600 | 0.73 | DTYMK (0.39) | — | |
| SCHEMBL9829900 | 0.67 | FAAH (0.59) | KAT2AKAT2BCASP3 | |
| SCHEMBL19426150 | 0.66 | TNF (0.53) | — | |
| SCHEMBL11268310 | 0.65 | DRD2 (0.38) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | ESR1 2529/4885ESR2 1265/4885KAT2A 747/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | ESR1 2241/4885ESR2 2096/4885KAT2A 288/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | ESR1 2529/4885ESR2 1265/4885KAT2A 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.